Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.

Read narrative

Sanofi Wettbewerber

Preisentwicklung & Leistung

Zusammenfassung der Höchst- und Tiefststände sowie der Veränderungen der Aktienkurse für Sanofi
Historische Aktienkurse
Aktueller Aktienkurs	€43.18
52-Wochen-Hoch	€53.36
52-Wochen-Tief	€43.10
Beta	0.28
1 Monat Veränderung	-7.79%
3 Monate Veränderung	-9.72%
1 Jahr Veränderung	-17.17%
3 Jahre Veränderung	-20.60%
5 Jahre Veränderung	-17.82%
Veränderung seit IPO	45.05%

Aktuelle Nachrichten und Updates

Recent updates

Seeking Alpha • Apr 20

What To Expect From Sanofi In Q1 2026

Summary On April 23, Sanofi will report its results for the first quarter of 2026. As a reminder, its revenue grew 23.1% year-over-year to $13.53 billion in Q4 last year. Meanwhile, Sanofi’s non-GAAP P/E ratio [FWD] is 9.66x, which, in my view, clearly indicates that it is trading at a discount. Also on April 13, Dupixent, its mega-blockbuster, received approval from the EC for the treatment of certain children with chronic spontaneous urticaria. Further, I'll discuss other factors that, in my view, make Sanofi's risk/reward profile even more attractive now that its stock is in the accumulation phase. Read the full article on Seeking Alpha

Seeking Alpha • Feb 19

Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth

Summary Sanofi's deep partnership with OpenAI could be a huge differentiating factor as OpenAI's agentic models grow in capabilities. OpenAI's "Deep Research" tool is already incredibly promising for Sanofi in its ability to dramatically boost the productivity of researchers. Sanofi's strong financials provide a solid base to fuel AI-driven growth. Sanofi still faces many competitive and regulatory challenges. Read the full article on Seeking Alpha

Seeking Alpha • Jan 29

Time To Be Bullish On Sanofi Ahead Of Its Earnings

Summary Dupixent continues leading among SNY’s portfolio, and it’s poised for up to $20 billion in peak sales. SNY’s recent Opella divestiture marks a pivot away from consumer health items like vitamins and supplements, bringing in roughly $8.7 billion in proceeds. SNY’s RSV vaccine, called Beyfortus, was a key driver for its previous quarter, and its Q4 could be a repeat since it’s typically seasonally strong for vaccines. The company also has a robust late-stage pipeline across multiple other indications, and I think we could see interesting updates for new IPs in 2025. Currently, SNY seems cheap relative to its peers, and the stock has yet to reach its previous 2024 highs. So, I think it’s a good time to buy SNY ahead of earnings. Read the full article on Seeking Alpha

Aktionärsrenditen

	SNY	US Pharmaceuticals	US Markt
7D	-7.3%	-1.9%	2.1%
1Y	-17.2%	33.3%	30.6%

Rendite im Vergleich zur Industrie: SNY unter dem Niveau der Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 33.3% erzielte.

Rendite vs. Markt: SNY hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 30.6 erzielte.

Preisvolatilität

Is SNY's price volatile compared to industry and market?
SNY volatility
SNY Average Weekly Movement	3.6%
Pharmaceuticals Industry Average Movement	9.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stabiler Aktienkurs: SNY hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.

Volatilität im Zeitverlauf: SNYDie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1994	74,846	Belen Garijo Lopez	www.sanofi.com

Sanofi beschäftigt sich mit der Erforschung, Entwicklung, Herstellung und Vermarktung von therapeutischen Lösungen. Das Unternehmen bietet Impfstoffe für die Bereiche Immunologie und Entzündungen, seltene Krankheiten, Neurologie, Onkologie und andere an. Darüber hinaus bietet es Kinderimpfstoffe gegen Poliomyelitis, Keuchhusten und Hämophilus influenzae Typ b (Hib), Schutz vor dem Respiratorischen Synzytialvirus und sechswertige Kombinationsimpfstoffe, die Hepatitis-A-, Typhus-, Gelbfieber- und Tollwutimpfstoffe umfassen.

Sanofi's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Sanofi im Vergleich zum Marktanteil des Unternehmens?
SNY grundlegende Statistiken
Marktanteil	US$103.90b
Gewinn(TTM)	US$5.67b
Umsatz(TTM)	US$55.59b

18.3x

Kurs-Gewinn-Verhältnis

1.9x

Kurs-Umsatz-Verhältnis

Ist SNY zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
SNY Gewinn- und Verlustrechnung (TTM)
Einnahmen	€47.35b
Kosten der Einnahmen	€13.09b
Bruttogewinn	€34.26b
Sonstige Ausgaben	€29.44b
Gewinn	€4.83b

Zuletzt gemeldete Gewinne

Mar 31, 2026

Datum des nächsten Gewinnberichts

Jul 30, 2026

Gewinn per Aktie (EPS)	4.02
Bruttomarge	72.36%
Nettogewinnspanne	10.20%
Schulden/Eigenkapital-Verhältnis	24.9%

Wie hat sich SNY auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

5.6%

Aktuelle Dividendenrendite

102%

Ausschüttungsquote

Zahlt SNY eine zuverlässige Dividende?

Siehe SNY Dividendenhistorie und Benchmarks

Bis wann müssen Sie SNY kaufen, um eine kommende Dividende zu erhalten?
Sanofi Dividendentermine
Ex-Dividenden Datum	May 04 2026
Datum der Dividendenzahlung	Jun 03 2026
Tage bis Ex-Dividende	6 days
Tage bis zum Datum der Dividendenzahlung	24 days

Zahlt SNY eine zuverlässige Dividende?

Siehe SNY Dividendenhistorie und Benchmarks

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2026/05/07 12:19
Aktienkurs zum Tagesende	2026/05/07 00:00
Gewinne	2026/03/31
Jährliche Einnahmen	2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Sanofi wird von 53 Analysten beobachtet. 18 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
null null	Banco de Sabadell. S.A.

Sanofi (SNY) Aktienübersicht

Belohnungen

Risikoanalyse

Looking to be second time lucky with a game-changing new product

Sanofi Wettbewerber

Bristol-Myers Squibb

Pfizer

Zoetis

Merck

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi Announces Board and Committee Changes

Sanofi Approves Ordinary Annual Dividend, Payable on May 7, 2026

Sanofi Recommends Cenrifki for EU Approval to Treat Secondary Progressive Multiple Sclerosis Without Relapses

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Sanofi Receives US Approval for Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children

Recent updates

Regeneron Pharmaceuticals, Inc. and Sanofi Demonstrate Dupixent Shows Improved Esophageal Function in Eosinophilic Esophagitis Phase 4 Trial

Sanofi Announces Board and Committee Changes

Sanofi Approves Ordinary Annual Dividend, Payable on May 7, 2026

Sanofi Recommends Cenrifki for EU Approval to Treat Secondary Progressive Multiple Sclerosis Without Relapses

Regeneron Pharmaceuticals, Inc. And Sanofi Announces Dupixent Approved In U.S. For Young Children With Uncontrolled Chronic Spontaneous Urticaria

Sanofi Receives US Approval for Tzield to Delay Onset of Stage 3 Type 1 Diabetes in Young Children

What To Expect From Sanofi In Q1 2026

Sanofi's Nuvaxovid Covid-19 Vaccine Showed Better Tolerability Than Mnexspike in Head-To-Head Study

Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria

Sanofi Becomes Market Authorization Holder for Nuvaxovid in Canada

Sanofi Announces Lunsekimig Meets Primary And Key Secondary Endpoints In Phase 2 Respiratory Studies In Asthma And CRSwNP

Sanofi Announces EU Approval of Rezurock for Treatment of Chronic Graft-Versus-Host Disease

Sanofi Presents New Results from Amlitelimab Phase 3 Studies in Atopic Dermatitis

Sanofi and Regeneron Receive Approval for Dupixent in Japan as First Targeted Medicine to Treat Adults with Bullous Pemphigoid

Sanofi Earns Breakthrough Therapy Designation in the Us for Venglustat for Type 3 Gaucher Disease

Sanofi, Annual General Meeting, Apr 29, 2026

Sanofi Announces Resignation of Patrick Kron as Independent Director and Chairman of the Nomination, Governance and Csr Committee

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Positive CHMP Opinion for Dupixent in Treating Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent (Dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (Afrs)

Sanofi's Rilzabrutinib Designates Breakthrough Therapy in the Us and Orphan Drug in Japan for the Treatment of Cold Autoimmune Hemolytic Anemia

Sanofi Announces Executive Changes

Sanofi Announces Chief Executive Officer Changes

Sanofi (ENXTPA:SAN) completed the acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX).

Sanofi's Venglustat Met All Primary Endpoints in A Phase 3 Study of Type 3 Gaucher Disease

Sanofi’s Rezurock Recommends for EU Approval by the CHMP to Treat Chronic Graft-vs-Host Disease

Sanofi Provides Earnings Guidance for the Year 2026

Sanofi Proposes Dividend for 2025

Sanofi's Amlitelimab Confirms its Potential in Atopic Dermatitis

Sanofi Announces Approval of Myqorzo and Redemplo in China

Sanofi's Tzield Accepts for Priority Review in the Us for Young Children with Stage 2 Type 1 Diabetes

Sanofi (ENXTPA:SAN) agreed to acquire Dynavax Technologies Corporation (NasdaqGS:DVAX) for $1.9 billion.

Sanofi Provides Update on Tolebrutinib in Primary Progressive Multiple Sclerosis

Sanofi's Qfitlia and Cablivi Approves in China, Expanding Care for Rare Diseases

Sanofi (ENXTPA:SAN) completed the acquisition of Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC.

Regeneron Pharmaceuticals, Inc. and Sanofi Announce European Commission Approves Dupixent (Dupilumab) for the Treatment of Moderate-To-Severe Chronic Spontaneous Urticaria (CSU)

Sanofi's Teizeild Recommends for EU Approval by the CHMP for Patients with Stage 2 Type 1 Diabetes

Sanofi Announces Positive Results from the pivotal LIBERTY- AFRS-AIMS Phase 3 Study

Sanofi Announces New Data from the Alphamedix-02 Phase 2 Study Evaluating Alphamedix

Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study

Sanofi's Tzield Accepts for Expanded Review in the US for Stage 3 Type 1 Diabetes Through FDA Commission's National Priority Voucher Pilot Program

Sanofi's High-Dose Influenza Vaccine Demonstrates Superior Protection for Older Adults Against Hospitalization vs Standard-Dose

Sanofi Provides Update on Regulatory Review in the EU for Rezurock to Treat Chronic Graft-Vs-Host Disease

Sanofi's Wayrilz Recommends for Eu Approval by the CHMP to Treat Immune Thrombocytopenia

Sanofi Announces Positive Results from the ALPHAMEDIX-02 Phase 2 Study

Sanofi to Report Q3, 2026 Results on Oct 30, 2026

Sanofi Expands Patient Affordable Program by Offering Access to All Its Insulins for $35 Per Month in the US

Sanofi Announces its SAR446268 Receives US Fast Track Designation for Treatment of Non-Congenital Myotonic Dystrophy Type 1

Thermo Fisher Scientific Inc. (NYSE:TMO) completed the acquisition of Steriles Manufacturing Site in Ridgefield, New Jersey of Sanofi (ENXTPA:SAN).

Sanofi Announces the Us Food and Drug Administration Approves Wayrilz (Rilzabrutinib) in US as First BTK Inhibitor for Immune Thrombocytopenia

Sanofi Confirms Earnings Guidance for the Year 2025

Sanofi's Sarclisa Approves in the EU for the Treatment of Transplant-Efficient Newly Diagnosed Multiple Myeloma

Sanofi Announces BEYFORTUS Reduced Hospital and Doctor Visits for RSV Disease in Babies by 87%

Sanofi (ENXTPA:SAN) entered into an agreement to acquire Vicebio Limited from Medicxi Ventures (UK) LLP, TCG Crossover Management, LLC, venBio LLC, Goldman Sachs Asset Management International, UniQuest Pty Limited and Avoro Capital Advisors LLC for $1.6 billion.

Sanofi (ENXTPA:SAN) completed the acquisition of Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC.

Sanofi's Sar446597 Earns Fast Track Designation in the US for Geographic Atrophy Due Toage-Related Macular Debutation

Sanofi Announces Riliprubart Granted Orphan Drug Designation in Japan for Chronic Inflammative Demyelinating Polyneuropathy

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves Dupixent (Dupilumab) for the Treatment of Adult Patients with Bullous Pemphigoid

Sanofi Accelerates Global Shipping of Beyfortus to Prepare Healthcare Providers Months Ahead of 2025-2026 RSV Season

American Society of Clinical Oncology Announces New Sarclisa Data Support Subcutaneous Administration with On-Body Injector

Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Phase 3 Trial, AERIFY-1, Evaluating the Investigational Use of itepekimab in Adults

Sanofi (ENXTPA:SAN) entered into a definitive merger agreement to acquire Vigil Neuroscience, Inc. (NasdaqGS:VIGL) for approximately $380 million.